Literature DB >> 35856401

A novel analytical framework for risk stratification of real-world data using machine learning: A small cell lung cancer study.

Luca Marzano1, Adam S Darwich1, Salomon Tendler2, Asaf Dan2, Rolf Lewensohn2, Luigi De Petris2, Jayanth Raghothama1, Sebastiaan Meijer1.   

Abstract

In recent studies, small cell lung cancer (SCLC) treatment guidelines based on Veterans' Administration Lung Study Group limited/extensive disease staging and resulted in broad and inseparable prognostic subgroups. Evidence suggests that the eight versions of tumor, node, and metastasis (TNM) staging can play an important role to address this issue. The aim of the present study was to improve the detection of prognostic subgroups from a real-word data (RWD) cohort of patients and analyze their patterns using a development pipeline with thoracic oncologists and machine learning methods. The method detected subgroups of patients informing unsupervised learning (partition around medoids) including the impact of covariates on prognosis (Cox regression and random survival forest). An analysis was carried out using patients with SCLC (n = 636) with stage IIIA-IVB according to TNM classification. The analysis yielded k = 7 compacted and well-separated clusters of patients. Performance status (Eastern Cooperative Oncology Group-Performance Status), lactate dehydrogenase, spreading of metastasis, cancer stage, and CRP were the baselines that characterized the subgroups. The selected clustering method outperformed standard clustering techniques, which were not capable of detecting meaningful subgroups. From the analysis of cluster treatment decisions, we showed the potential of future RWD applications to understand disease, develop individualized therapies, and improve healthcare decision making.
© 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35856401      PMCID: PMC9579402          DOI: 10.1111/cts.13371

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.438


  45 in total

1.  Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.

Authors:  Toshiaki Takahashi; Takeharu Yamanaka; Takashi Seto; Hideyuki Harada; Hiroshi Nokihara; Hideo Saka; Makoto Nishio; Hiroyasu Kaneda; Koichi Takayama; Osamu Ishimoto; Koji Takeda; Hiroshige Yoshioka; Motoko Tachihara; Hiroshi Sakai; Koichi Goto; Nobuyuki Yamamoto
Journal:  Lancet Oncol       Date:  2017-03-23       Impact factor: 41.316

Review 2.  Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysis.

Authors:  Xiuxiu Zhang; Mengfei Guo; Jinshuo Fan; Zhilei Lv; Qi Huang; Jieli Han; Feng Wu; Guorong Hu; Juanjuan Xu; Yang Jin
Journal:  Cancer Biomark       Date:  2016       Impact factor: 4.388

3.  Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study.

Authors:  Salomon Tendler; Yiqiang Zhan; Andreas Pettersson; Rolf Lewensohn; Kristina Viktorsson; Fang Fang; Luigi De Petris
Journal:  Acta Oncol       Date:  2020-01-07       Impact factor: 4.089

4.  Prophylactic cranial irradiation in patients with small cell lung cancer. A retrospective study of recurrence, survival and morbidity.

Authors:  A Ramlov; A Tietze; A A Khalil; M M Knap
Journal:  Lung Cancer       Date:  2012-06-05       Impact factor: 5.705

5.  Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease?

Authors:  Patrick Micke; Andreas Faldum; Tsegay Metz; Kai-Michael Beeh; Fernando Bittinger; Jan-Georg Hengstler; Roland Buhl
Journal:  Lung Cancer       Date:  2002-09       Impact factor: 5.705

6.  Role of mTOR As an Essential Kinase in SCLC.

Authors:  Jeffrey A Kern; Jihye Kim; Daniel G Foster; Rangnath Mishra; Eric E Gardner; John T Poirier; Christopher Rivard; Hui Yu; James H Finigan; Afshin Dowlati; Charles M Rudin; Aik-Choon Tan
Journal:  J Thorac Oncol       Date:  2020-06-26       Impact factor: 15.609

7.  Expanding TNM for lung cancer through machine learning.

Authors:  Matthew Hueman; Huan Wang; Zhenqiu Liu; Donald Henson; Cuong Nguyen; Dean Park; Li Sheng; Dechang Chen
Journal:  Thorac Cancer       Date:  2021-03-13       Impact factor: 3.500

8.  All Models are Wrong, but Many are Useful: Learning a Variable's Importance by Studying an Entire Class of Prediction Models Simultaneously.

Authors:  Aaron Fisher; Cynthia Rudin; Francesca Dominici
Journal:  J Mach Learn Res       Date:  2019       Impact factor: 5.177

9.  Big Data Toolsets to Pharmacometrics: Application of Machine Learning for Time-to-Event Analysis.

Authors:  Xiajing Gong; Meng Hu; Liang Zhao
Journal:  Clin Transl Sci       Date:  2018-03-13       Impact factor: 4.689

10.  Integrated Genome-Wide Analysis of Gene Expression and DNA Copy Number Variations Highlights Stem Cell-Related Pathways in Small Cell Esophageal Carcinoma.

Authors:  Di Liu; Xinyan Xu; Junmiao Wen; Liyi Xie; Junhua Zhang; Yuxin Shen; Guoliang Jiang; Jiayan Chen; Min Fan
Journal:  Stem Cells Int       Date:  2018-08-30       Impact factor: 5.443

View more
  1 in total

1.  A novel analytical framework for risk stratification of real-world data using machine learning: A small cell lung cancer study.

Authors:  Luca Marzano; Adam S Darwich; Salomon Tendler; Asaf Dan; Rolf Lewensohn; Luigi De Petris; Jayanth Raghothama; Sebastiaan Meijer
Journal:  Clin Transl Sci       Date:  2022-07-29       Impact factor: 4.438

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.